Network News

PEPperPRINT GmbH: EU-Funded TRANSCAN-3 Project Marks Key Milestones in Personalized Immunotherapy for Esophageal Cancer

The TRANSCAN-3 project (T-PLEX EAC), funded by the European Union, is approaching the end of its second year with significant progress in developing personalized adoptive T cell therapies for patients with esophageal adenocarcinoma (EAC). EAC remains the most common esophageal cancer in Western populations, and despite advances in chemotherapy, radiotherapy, and surgery, only around 20% […]

Inflammation rewires bone marrow microenvironment long before leukaemias develop

New research suggests that inflammatory support cells play a key role in damaging bone marrow early in cancer development – potentially offering a new target for treatments that stop blood disorders before becoming cancerous. Summary The following news article is an amended version of a news release from UMC Mainz Office of Communications, published with […]

BioMed X Announces New Neuroscience Research Collaboration in the USA

New Haven, CT, USA, November 25, 2025 – BioMed X, a leading external innovation hub for pharma, announced today the launch of a new collaborative research project with AbbVie, hosted at the BioMed X Institute in New Haven, Connecticut. The topic of the new research project in the field of neuroscience is the development of “Circuit-Based Model […]

New data initiative accelerates discovery and personalised care for mental health conditions

EMBL-EBI receives UKRI Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR) funding for enhancing and translating mental-health omics data into the Open Targets Platform Summary Identifying targets for new treatments for mental health conditions could become faster, thanks to a new initiative that, for the first time, will bring patient […]

Malaria Parasites Move on Right-Handed Helices

Motion patterns help the transition between tissue compartments – explanation for asymmetry in the body plan of the pathogen With victims numbering in the millions, malaria is an infectious disease caused by the bite of a mosquito carrying the malaria parasite. After penetrating the skin, the pathogen moves with helical trajectories. It almost always turns […]

New Capital Strengthens ProtaGene’s Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy Markets

HEILBRONN, Germany and BOSTON, Nov. 20, 2023 /PRNewswire/ — ProtaGene, a leading global contract research organization (CRO) dedicated to advanced analytics for biologics and cell and gene therapies, today announced additional investment from Ampersand Capital Partners. Given the critical importance of advanced bioanalytics and product characterization for developing increasingly complex therapeutics, Ampersand has invested nearly $40 million within the past year […]

Shield against metastases and genetically protected CAR-T cells: Double honor for Mirco Julian Friedrich

Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital (UKHD) has received two awards for two independent research projects: The Beug Foundation has honored his novel approach to preventing liver metastases with the Metastasis Prize 2025. The Kind-Philipp Research Prize […]

Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer

Ladenburg, Germany, 24 November 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the Supervisory Board has revoked the appointment of Professor Andreas Pahl as member of the Executive Management Board and Chief Executive Officer, and has instead appointed Dr Dongzhou Jeffery Liu as Chairman […]

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Paris and Tarrytown, NY, November 25, 2025. The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response […]